Precision Biosciences (DTIL) EBT Margin (2018 - 2026)
Precision Biosciences' (DTIL) quarterly EBT Margin came in at 79.12% in Q1 2026, up 7327605.0% year-on-year from N/an in Q1 2025, and down 318.37% on a QoQ basis from 36.23% in Q4 2025.
Precision Biosciences (DTIL) EBT Margin (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of EBT Margin data on file, last reported at 79.12% in Q1 2026.
- On a quarterly basis, EBT Margin rose 7327605.0% year-over-year to 79.12% in Q1 2026; TTM through Mar 2026 was 102.05%, a 1336.0% increase from a year earlier, with the FY2025 full-year figure at 563.83%, down 33635.0% from the prior year.
- EBT Margin for Q1 2026 stood at 79.12%, down from 36.23% in the prior quarter.
- Over the last five years, EBT Margin for DTIL reached as high as 36.23% in Q4 2025 and fell as low as 212653.85% in Q3 2025.
- Historically, EBT Margin has averaged 24751.74% across 5 years, with a median of 190.59% in 2022.
- Across the five-year window, EBT Margin plunged 20753857 bps in 2025 and soared 7327605 bps in 2026, its largest moves.
- Year by year, EBT Margin stood at 113.36% in 2022, then plunged by 73 bps to 196.11% in 2023, then plunged by 1806 bps to 3738.24% in 2024, then jumped by 101 bps to 36.23% in 2025, then plunged by 318 bps to 79.12% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 79.12% in Q1 2026, 36.23% in Q4 2025, and 212653.85% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Precision Biosciences | 178.85 Mn | 150.56 Mn | - | -79.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.12% |
| Dec 31, 2025 | 36.23% |
| Sep 30, 2025 | -212,653.85% |
| Jun 30, 2025 | -123,161.11% |
| Mar 31, 2025 | -73,355.17% |
| Dec 31, 2024 | -3,738.24% |
| Sep 30, 2024 | -5,115.28% |
| Jun 30, 2024 | 31.20% |
| Mar 31, 2024 | -17.62% |
| Dec 31, 2023 | -196.11% |
| Sep 30, 2023 | -82.24% |
| Jun 30, 2023 | -38.31% |
| Mar 31, 2023 | -135.34% |
| Dec 31, 2022 | -113.36% |
| Sep 30, 2022 | -190.59% |
| Jun 30, 2022 | -938.82% |
| Mar 31, 2022 | -1,031.93% |
| Dec 31, 2021 | -485.20% |
| Sep 30, 2021 | -92.04% |
| Jun 30, 2021 | 28.41% |